Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

4.090 +0.020 (+0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 365,151
Open 4.050
Bid (Size) 4.040 (68)
Ask (Size) 4.100 (1)
Prev. Close 4.070
Today's Range 3.961 - 4.148
52wk Range 2.833 - 11.00
Shares Outstanding 14,508,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) to a Securities Class Action Deadline on October 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) to a Securities Class Action Deadline on October 14, 2025
Via TheNewswire.com
Topics Lawsuit

Performance

YTD
-48.4%
-48.4%
1 Month
-9.1%
-9.1%
3 Month
-28.2%
-28.2%
6 Month
-31.3%
-31.3%
1 Year
+3.8%
+3.8%

More News

Read More
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY
Via NewMediaWire
Topics Fraud Lawsuit
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY
Via TheNewswire.com
Topics Fraud Lawsuit
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
Unicycive Posts 65% EPS Gain in Q2
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
From Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
From Pomerantz LLP
Via GlobeNewswire
Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations
Via NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations
Via TheNewswire.com
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Which stocks are moving on Monday?
Via Chartmill
FDA Raises Manufacturing Concerns, Delays Unicycive's Kidney Disease Drug Approval
Via Benzinga
Gapping stocks in Monday's session
Via Chartmill

Frequently Asked Questions

Is Unicycive Therapeutics, Inc. - Common Stock publicly traded?
Yes, Unicycive Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Unicycive Therapeutics, Inc. - Common Stock trade on?
Unicycive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Unicycive Therapeutics, Inc. - Common Stock?
The ticker symbol for Unicycive Therapeutics, Inc. - Common Stock is UNCY on the Nasdaq Stock Market
What is the current price of Unicycive Therapeutics, Inc. - Common Stock?
The current price of Unicycive Therapeutics, Inc. - Common Stock is 4.090
When was Unicycive Therapeutics, Inc. - Common Stock last traded?
The last trade of Unicycive Therapeutics, Inc. - Common Stock was at 08/20/25 04:00 PM ET
What is the market capitalization of Unicycive Therapeutics, Inc. - Common Stock?
The market capitalization of Unicycive Therapeutics, Inc. - Common Stock is 59.34M
How many shares of Unicycive Therapeutics, Inc. - Common Stock are outstanding?
Unicycive Therapeutics, Inc. - Common Stock has 59M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.